CASY vs GSK · P/E 36, rev $17.56B vs P/E 13, $103.31B cap
Caseys General Stores Inc (CASY) versus GlaxoSmithKline PLC ADR (GSK) — a side-by-side from cached financials, not a winner call.
Caseys General Stores Inc (CASY) is a specialty retail company listed on US.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Latest reported CASY revenue for 2026-04-30 was $17.56B. Net income was $714.4M. Revenue was up 10.2% from 2025-04-30 to 2026-04-30. CASY currently screens at market cap $19.56B and trailing P/E 36.0.
GSK does not have a complete income-statement cache yet.
CASY currently screens at market cap $19.56B and trailing P/E 36.0. GSK currently screens at market cap $103.31B and trailing P/E 13.5.
Not investment advice. Open the CASY and GSK stock pages for the full models.
Not investment advice.